Vivet Therapeutics SAS

https://www.vivet-therapeutics.com

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain. Vivet’s lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC). This rare genetic disorder is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damage, neurologic symptoms and potentially death. Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners. *

	Start	2016-07-26 established
	Group	Vívet Therapeutics (Group)
	Industry	Anc80 AAV gene therapy vector
	Industry 2	VTX-801 (Vivet Therapeutics)
	Person	Combal, Jean-Philippe (Vivet Therapeutics 201705 CEO + Co-Founder before Gensight Biologics + Sanofi)
	Person 2	Gonzalez Aseguinolaza, Gloria (Vivet Therapeutics 201705 CSO + Co-Founder)

	Region	Paris
	Country	France
	Street	29 rue Tronchet
	City	75008 Paris
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Vivet Therapeutics SAS. (3/20/19). "Press Release: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics". Paris & New York, NY.

		Record changed: 2024-03-30